Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
21/06/2023 | 22:07 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:SMFR | Sema4 Holdings Corporation |
20/06/2023 | 23:17 | Edgar (US Regulatory) | Current Report Filing (8-k) | NASDAQ:SMFR | Sema4 Holdings Corporation |
09/06/2023 | 22:16 | Edgar (US Regulatory) | Amended Statement of Ownership (sc 13g/a) | NASDAQ:SMFR | Sema4 Holdings Corporation |
25/04/2023 | 23:25 | Edgar (US Regulatory) | Securities Registration: Employee Benefit Plan (s-8) | NASDAQ:SMFR | Sema4 Holdings Corporation |
20/04/2023 | 22:28 | Edgar (US Regulatory) | Amended Statement of Beneficial Ownership (sc 13d/a) | NASDAQ:SMFR | Sema4 Holdings Corporation |
10/02/2023 | 22:06 | Edgar (US Regulatory) | Initial Statement of Beneficial Ownership (3) | NASDAQ:SMFR | Sema4 Holdings Corporation |
01/02/2023 | 23:12 | Edgar (US Regulatory) | Statement of Ownership (sc 13g) | NASDAQ:SMFR | Sema4 Holdings Corporation |
30/01/2023 | 23:14 | Edgar (US Regulatory) | Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) | NASDAQ:SMFR | Sema4 Holdings Corporation |
09/01/2023 | 14:30 | GlobeNewswire Inc. | Sema4 Announces Name Change to GeneDx and Provides Preliminary 2022 Financial Results and 2023 Guidance | NASDAQ:SMFR | Sema4 Holdings Corporation |
30/12/2022 | 14:30 | GlobeNewswire Inc. | Sema4|GeneDx to Participate in the 41st Annual J.P. Morgan Healthcare Conference | NASDAQ:SMFR | Sema4 Holdings Corporation |
05/12/2022 | 14:00 | GlobeNewswire Inc. | New Research from Sema4|GeneDx Highlights the Importance of Rapid Exome Sequencing for Diagnosing Mitochondrial Diseases in the NICU | NASDAQ:SMFR | Sema4 Holdings Corporation |
14/11/2022 | 14:02 | GlobeNewswire Inc. | Sema4 Reports Third Quarter 2022 Financial Results and New Strategic Direction | NASDAQ:SMFR | Sema4 Holdings Corporation |
04/11/2022 | 21:05 | GlobeNewswire Inc. | Sema4 to Report Third Quarter 2022 Financial Results on Monday, November 14th, 2022 | NASDAQ:SMFR | Sema4 Holdings Corporation |
04/11/2022 | 10:45 | PR Newswire (US) | SMFR SHAREHOLDER ALERT: Jakubowitz Law Reminds Sema4 Holdings Corp. Shareholders of a Lead Plaintiff Deadline of November 7, 2022 | NASDAQ:SMFR | Sema4 Holdings Corporation |
03/11/2022 | 03:50 | PR Newswire (US) | FILING DEADLINE--Kuznicki Law PLLC Announces Class Action on Behalf of Shareholders of Sema4 Holdings Corp. - SMFR | NASDAQ:SMFR | Sema4 Holdings Corporation |
02/11/2022 | 10:45 | PR Newswire (US) | SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Sema4 Holdings, Corp. of a Class Action Lawsuit and a Lead Plaintiff Deadline of November 7, 2022 - (NASDAQ: SMFR) | NASDAQ:SMFR | Sema4 Holdings Corporation |
31/10/2022 | 14:00 | GlobeNewswire Inc. | Sema4|GeneDx Commends New Evidence-Based Guidelines from the National Society of Genetic Counselors Recommending Exome Sequencing as a First-Tier Genetic Test for Unexplained Epilepsies | NASDAQ:SMFR | Sema4 Holdings Corporation |
27/10/2022 | 14:00 | GlobeNewswire Inc. | Sema4|GeneDx Announces Results from Phase 1 of SeqFirst Study, Demonstrating Broad Utility of Rapid Whole Genome Sequencing for Critically Ill Newborns | NASDAQ:SMFR | Sema4 Holdings Corporation |
26/10/2022 | 14:00 | GlobeNewswire Inc. | Sema4|GeneDx collaborates on new research demonstrating genome and exome sequencing deliver more diagnostic certainty than multi-gene panels | NASDAQ:SMFR | Sema4 Holdings Corporation |
13/10/2022 | 14:00 | GlobeNewswire Inc. | Study Demonstrates the Utility of Exome Sequencing for Diagnosing Autism Spectrum Disorders | NASDAQ:SMFR | Sema4 Holdings Corporation |
05/10/2022 | 14:00 | GlobeNewswire Inc. | Sema4|GeneDx To Provide Whole Genome Sequencing and Interpretation Services for Landmark Genomic Newborn Screening Study | NASDAQ:SMFR | Sema4 Holdings Corporation |
08/09/2022 | 12:04 | Edgar (US Regulatory) | Notice of Effectiveness (effect) | NASDAQ:SMFR | Sema4 Holdings Corporation |
07/09/2022 | 23:26 | Edgar (US Regulatory) | Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) | NASDAQ:SMFR | Sema4 Holdings Corporation |
26/08/2022 | 22:56 | Edgar (US Regulatory) | Securities Registration Statement (simplified Form) (s-3) | NASDAQ:SMFR | Sema4 Holdings Corporation |
26/08/2022 | 14:00 | GlobeNewswire Inc. | Sema4 Appoints Healthcare and Diagnostics Industry Veteran Kevin Feeley as Chief Financial Officer | NASDAQ:SMFR | Sema4 Holdings Corporation |
18/08/2022 | 05:25 | TipRanks | BTIG Sticks to Their Buy Rating for Sema4 Holdings (SMFR) | NASDAQ:SMFR | Sema4 Holdings Corporation |
15/08/2022 | 22:47 | Edgar (US Regulatory) | Quarterly Report (10-q) | NASDAQ:SMFR | Sema4 Holdings Corporation |
15/08/2022 | 22:05 | GlobeNewswire Inc. | Sema4 Announces Continued Restructuring, Business Highlights, and Reports Second Quarter 2022 Financial Results | NASDAQ:SMFR | Sema4 Holdings Corporation |
15/08/2022 | 22:05 | GlobeNewswire Inc. | Sema4 Announces Changes to its Research & Development Leadership | NASDAQ:SMFR | Sema4 Holdings Corporation |
26/07/2022 | 14:00 | GlobeNewswire Inc. | Sema4 to Report Second Quarter 2022 Financial Results on Monday, August 15, 2022 | NASDAQ:SMFR | Sema4 Holdings Corporation |